Provided by Tiger Trade Technology Pte. Ltd.

Abivax S.A.

117.61
+0.23000.20%
Post-market: 118.000.3900+0.33%19:45 EDT
Volume:443.37K
Turnover:52.19M
Market Cap:9.31B
PE:-20.72
High:119.06
Open:117.42
Low:115.63
Close:117.38
52wk High:148.83
52wk Low:5.59
Shares:79.19M
Float Shares:42.66M
Volume Ratio:0.51
T/O Rate:1.04%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-5.6758
EPS(LYR):-5.6758
ROE:-135.58%
ROA:-38.95%
PB:17.44
PE(LYR):-20.72

Loading ...

Company Profile

Company Name:
Abivax S.A.
Exchange:
NASDAQ
Establishment Date:
2013
Employees:
69
Office Location:
7-11 Boulevard Haussmann,Paris,Ile-de-France,France
Zip Code:
75009
Fax:
- -
Introduction:
ABIVAX Société Anonyme, a clinical-stage biotechnology company, focuses on developing therapeutics that harness the body's natural regulatory mechanisms to modulate the immune response in patients with chronic inflammatory diseases. The company is evaluating its lead drug candidate, obefazimod, in Phase 3 clinical trials for the treatment of moderately to severely active ulcerative colitis. ABIVAX Société Anonyme was incorporated in 2013 and is headquartered in Paris, France.

Directors

Name
Position
Marc de Garidel
Chief Executive Officer and Director
Camilla Soenderby
Independent Director
Corinna zur Bonsen Thomas
Independent Director
Dominik Höchli
Independent Director
June Lee
Independent Director
Sylvie Grégoire
Board Chair and Independent Director
Troy Ignelzi
Independent Director

Shareholders

Name
Position
Marc de Garidel
Chief Executive Officer and Director
Didier Blondel
Executive Vice President, Chief Financial Officer and Board Secretary
Fabio Cataldi
Chief Medical Officer